Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Cash & Current Investments: 2019-2024

Historic Cash & Current Investments for Keros Therapeutics (KROS) over the last 6 years, with Dec 2024 value amounting to $559.9 million.

  • Keros Therapeutics' Cash & Current Investments rose 30.68% to $693.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 billion, marking a year-over-year increase of 55.79%. This contributed to the annual value of $559.9 million for FY2024, which is 69.09% up from last year.
  • According to the latest figures from FY2024, Keros Therapeutics' Cash & Current Investments is $559.9 million, which was up 69.09% from $331.1 million recorded in FY2023.
  • Over the past 5 years, Keros Therapeutics' Cash & Current Investments peaked at $559.9 million during FY2024, and registered a low of $230.0 million during FY2021.
  • Over the past 3 years, Keros Therapeutics' median Cash & Current Investments value was $331.1 million (recorded in 2023), while the average stood at $390.0 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first skyrocketed by 3,687.41% in 2020, then dropped by 13.48% in 2021.
  • Yearly analysis of 5 years shows Keros Therapeutics' Cash & Current Investments stood at $265.9 million in 2020, then dropped by 13.48% to $230.0 million in 2021, then climbed by 21.30% to $279.0 million in 2022, then rose by 18.67% to $331.1 million in 2023, then spiked by 69.09% to $559.9 million in 2024.